NCT06340165View on ClinicalTrials.gov

A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer

RecruitingOBSERVATIONAL
Enrollment

153

Participants

Timeline

Start Date

February 4, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Breast Cancer
Interventions
DRUG

Anlotinib

Anrotinib is available in 12 mg, 10 mg, and 8 mg doses. The recommended dose of Anrotinib is 12 mg taken by mouth once daily, continuously, for 2 weeks on and 1 week off, in a 21-day cycle.

Trial Locations (1)

130021

RECRUITING

The First Affiliated Hospital of Jilin University, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER